Gronghui October 23 | Zhongtai International released a research report saying that the federal pharmaceutical rating was raised from "buy" to "overweight", and the target price rose slightly from HK $9.68 to HK $9.7. As sales of the insulin and animal protection business in the second half of 2023 are expected to be better than earlier forecasts, revenue forecasts for 2023-25e will be raised by 2.1 per cent, 1.7 per cent and 1.9 per cent, and net profit forecasts for shareholders by 0.4 per cent, 1.2 per cent and 0.3 per cent. According to the report, the company's management said that the first GLP-1 agonist liraluptide has submitted an application for listing, which is expected to be approved within 2024. According to the current progress, the company expects that long-acting insulin Degu insulin is expected to be approved for sale in 2025. With regard to the recent market concern, the company is currently conducting clinical trials and is expected to approve diabetes and weight management indications in 2025 and 2027, respectively. The company is one of the companies listed in Hong Kong that have been approved for the clinical trial of Simiguelu. because of its excellent effect in reducing blood sugar and weight loss, it will be concerned by funds if the clinical data are good in the future.